ESTRO 2025 - Abstract Book

S1866

Clinical – Upper GI

ESTRO 2025

Conclusion: PT is associated with a significantly lower PPC rate than XT. PT dose-response data should be included in NTCP modeling to avoid overestimating PT complication risk, especially in the context of model-based patient selection for PT. Keywords: Esophageal cancer, NTCP, Proton-therapy References: 1. Muijs, C. et al. PD-0878 Reduction of post-operative toxicity in esophageal cancer patients after model based proton therapy. Radiother. Oncol. 161 , S714–S715 (2021) Digital Poster The role of Stereotactic Body Radiation Therapy in the treatment of oligometastatic hepatocellular carcinoma Lorenzo Lo Faro 1 , Veronica Vernier 1 , Tiziana Comito 1 , Maria Massaro 1 , Madalina B La Rocca 2 , Beatrice Marini 1 , Luciana Di Cristina 1 , Maria Ausilia Teriaca 1 , Davide Franceschini 1 , Ciro Franzese 1 , Marta Scorsetti 1 1 Radiation Oncology, Humanitas Research Hospital, Rozzano, Italy. 2 Radiation Oncology, Messina, Messina, Italy Purpose/Objective: Oligometastatic hepatocellular carcinoma (HCC) poses significant treatment challenges due to its aggressive nature and limited therapeutic options. The oncological benefit of local ablative therapy for oligometastatic disease (OMD), such as Stereotactic Body Radiation Therapy (SBRT), have been recently proven by several randomized trials. However, the OMD concept or SBRT benefits have not been well-defined in HCC. The aim of the study is to retrospectively collect data of patients affected by oligometastatic HCC treated with SBRT, to identify outcome in terms of local control, overall survival and feasibility. Material/Methods: Patients affected by HCC with extra-hepatic OMD were treated with linac-based SBRT with doses ranging from 30 to 50 Gy in 4 to 10 fractions with VMAT technique, according to organs and treated sites. Primary endpoint was local control (LC), secondary endpoints were overall survival (OS), toxicity and any potential prognostic features. 4278